



GENOA
Italy

March 13-15



ECCN
11th edition
2023

EUROPEAN
CONFERENCE ON
CLINICAL
NEUROIMAGING

/// PROGRAM ///



• Summary

Edito	4
Scientific Committee	5
General information	6
Planning	7
Program	8 - 13
Monday 13th, March.....	8
Tuesday 14th, March	9
Wednesday 15th, March	12
Notes	14 - 15

The 11th European Conference on Clinical Neuroimaging (ECCN, March 13-15, 2023) will again bring together physicians and researchers of all imaging modalities (from PET, to SPECT and MRI imaging) and a window will also be opened on blood biomarkers and emerging technologies.

We look forward to seeing you in Genoa to discuss about clinical neuroimaging and science.

Silvia Morbelli,

Associate Professor Nuclear Medicine Department of Health Sciences University of Genoa, Italy

Franck Semah,

Professor, Head of Imaging Department, University Hospital of Lille, France



Scientific Committee

Nathalie Albert (Munich, Germany)

Henryk Barthel (Leipzig, Germany)

Bart Van Berckel (Amsterdam, Netherlands)

Ronald Boellaard (Groningen, Netherlands)

Matthias Brendel (Munich, Germany)

Diego Cecchin (Padova, Italy)

Andrea Chincarini (Genoa, Italy)

Maria Luisa De Rimini (Naples, Italy)

Ozgul Ekmekcioglu (Istanbul, Turkey)

Francesco Fraioli (London, UK)

Valentina Garibotto (Geneva, Switzerland)

Eric Guedj (Marseille, France)

Adriaan Lammertsma (Amsterdam, Netherlands)

Ian Law (Copenhagen, Denmark)

Silvia Morbelli (Genoa, Italy)

Marco Pagani (Roma, Italy)

Sabina Pappata (Naples, Italy)

Matteo Pardini (Genoa, Italy)

John Prior (Lausanne, Switzerland)

Franck Semah (Lille, France)

Stelvio Sestini (Florence, Italy)

Nelleke Tolboom (Utrecht, Netherlands)

Tatjana Traub-Weidinger (Vienna, Austria)

Antonio Uccelli (Genoa, Italy)

Elsmarieke Van de Giessen (Amsterdam, Netherlands)

Donatienne Van Weehaeghe (Gent, Belgium)

Antoine Verger (Nancy, France)

General information



Registration and Congress secretariat

Name badges and attendee bags can be collected from the registration desk located by the conference room



Certificates of attendance

Certificates of attendance can be collected from the registration desk.



Wireless connection

A free wireless internet connection will be available.



Photography and recording of programs

The ECCN strictly prohibits all unauthorized photography, audio and/or videotaping during the meeting.



Coffee breaks

Coffee breaks will be served close to the registration area.

Congress venue



NH Collection Genova Marina hotel

Molo Ponte Calvi, 5
16124 Genoa, Italy

FROM TRAIN STATION

From Darsena metro stop: The hotel is 230 meters away.

Closest metro station: Darsena metro
Ticket (100 min): 1.50€ Ticket (24h): 4.50€

BY CAR

Parking: Onsite. €1.80 / hour. €20.00 / day.
Parking cannot be reserved in advance.



Congress secretariat
ANT CONGRES

+33 4 67 10 92 23
eccn-congress@ant-congres.com



Co-organizer
ADRINORD

+33 3 28 38 50 27
contact@adrinord.fr

● Planning

MONDAY
13

1.00 - 2.00 PM	2.00 - 3.30 PM	3.30 - 4.00 PM	4.00 - 5.30 PM	5.30 - 6.15 PM
REGISTRATION	LECTURE SESSION 1	COFFEE BREAK	ORAL COMMUNICATION 1	INDUSTRY SYMPOSIUM 1

TUESDAY
14

8.30 - 9.50 AM	9.50 - 10.30 AM	10.30 AM - 12.00 PM	12.00 - 12.45 PM	12.45 - 2.00 PM
ORAL COMMUNICATION 2	AWARD & COFFEE BREAK	LECTURE SESSION 2	INDUSTRY SYMPOSIUM 2	LUNCH
2.00 - 3.30 PM	3.30 - 4.00 PM	4.00 - 5.15 PM	5.15 - 6.00 PM	6.00 - 6.30 PM
LECTURE SESSION 3	COFFEE BREAK	ORAL COMMUNICATION 3	INDUSTRY SYMPOSIUM 3	RAPID FIRE SESSION

WEDNESDAY
15

8.30 - 10.00 AM	10.00 - 10.30 AM	10.30 AM - 12.00 PM	12.00 - 1.55 PM	1.25 PM
ORAL COMMUNICATION 4	COFFEE BREAK	LECTURE SESSION 4	RAPID FIRE SESSION 2	END OF THE CONGRESS

Program

Monday 13th March

1:00 PM REGISTRATION

1:45 PM WELCOME | Chair: *Silvia Morbelli*

2:00 PM Lecture session 1: Emerging biomarkers in neurodegenerative diseases

Chairs: *Henryck Barthel & Franck Semah*

2:00 PM Clinical use of TAU PET: are we ready?
Matthias Brendel (Munich, Germany)

2:30 PM Plasma screening: a game changer for diagnostic algorithms.
Kaj Blennow (Göteborg, Sweden)

3:00 PM Tau biomarkers in Alzheimer's disease: towards implementation in clinical trials.
Rik Ossenkoppele (Amsterdam, Netherlands)

3:30 PM Coffee Break

4:00 PM Oral communications session 1

Chairs: *Marco Pagani & Donatienne Van Weehaeghe*

4:00 PM Use of brain 2-[18F]FDG-PET to discriminate ALS and ALS-mimics.
Antonio Canosa (Italy)

4:08 PM Positron emission tomography with [18F]-DPA-714 unveils a smoldering component in most multiple sclerosis lesions which drives disease progression.
Mariem Hamzaoui (France)

4:16 PM Coupled or decoupled? Association between patterns of tau pathology and longitudinal neurodegeneration in Alzheimer's Disease.
Rosaleena Mohanty (Sweden)

4:24 PM A 3D neural network to classify subjects as Alzheimer's disease, frontotemporal dementia or healthy controls using brain 18F-FDG PET.
Antoine Rogeau (France)

4:32 PM The impact of tau deposition and hypometabolism on cognitive impairment and longitudinal cognitive decline.
Cecilia Boccalini (Switzerland)

4:40 PM Subtraction of Interictal Predicted versus clinical [18F]FDG-PET Co-registered to MRI (SIPCOM) versus SPM for detecting of the epileptogenic zone.
Anthime Flaus (France)

4:48 PM Interest of the initial characterization of cerebral lesion by amino-acid PET in addition to conventional MRI in routine care.
Antoine Verger (France)

4:56 PM Cognitive implication of amygdalar substructures in lesional and non-lesional Temporal Lobe Epilepsy.
Alice Ballerini (Italy)

5:04 PM Deciphering sources of PET signals in the tumor microenvironment of glioblastoma at cellular resolution.
Laura Bartos (Germany)

5:12 PM Assessment of brain FDG-PET studies in non-lesional epilepsy: a new simulation-based framework for ground-truth standardization PET studies evaluation.
Aida Niñerola-Baizán (Spain)

5:30 PM Industry symposium 1 - Brain Motion management with SIGNA™ PET/MR

Chair : *Franck Semah*

Maria Picchio & Paola Scifo (IRCCS Ospedale San Raffaele, Milan, Italy)



GE HealthCare

6:15 PM End of the day



Tuesday 14th March (Morning)

8:30 AM	Oral communications session 2 <i>Chairs: Matthias Brendel & Lyduine Collij</i>
8:30 AM	3R Pick Tau Imaging in Frontotemporal Lobar Degeneration – A Multi-Centre [18F] PI-2620 PET Study. <i>Henryk Barthel (Germany)</i>
8:38 AM	Parkinson's disease subtypes based on MRI identified in 4 different cohorts. <i>Anna Inguanzo (Sweden)</i>
8:46 AM	Mapping Brain metabolism and neurotransmitter dysfunction in early and late onset dementia with Lewy bodies. <i>Lorenzo Maria Jonghi-Lavarini (Italy)</i>
8:54 AM	Are [18F]FDG metabolic alterations in Amyotrophic Lateral Sclerosis (ALS) correlated with chitinases and neurofilaments concentrations? <i>Andrea Osele (Italy)</i>
9:02 AM	Disease-tailored z-score cut-offs for striatal binding ratio of DaT SPECT for the diagnosis of Dementia with Lewy Bodies (DLB): a multicenter study. <i>Francesco Lanfranchi (Italy)</i>
9:10 AM	[18 F]FDG PET/CT DEep LEarning Model to Classify PriMary Parkinson's disease, Atypical PARKinsonian Disorders and healthy controls (Delemma-PARK). <i>Gayane Aghakhanyan (Italy)</i>
9:18 AM	Validation of the REM Behaviour Disorder phenoconversion-related pattern in an independent Cohort. <i>Beatrice Orso (Italy)</i>
9:26 AM	Head-to-Head Comparison of PET and ASL-MRI BBB Permeability measurements for Dementia Imaging: Study Protocol. <i>Paulien Moyaert (Belgium)</i>
9:34 AM	Sex-related differences in Amyotrophic Lateral Sclerosis: a brain 2-[18F]FDG-PET study. <i>Giulia Polverari (Italy)</i>
9:42 AM	FDG-PET shows weak correlation between focal motor weakness and brain metabolic alterations in ALS. <i>Stefan Sennfalt (Sweden)</i>
9:50 AM	Award <i>Chairs: Silvia Morbelli & Franck Semah</i>
10:00 AM	Coffee Break
10:30 AM	Lecture session 2 : Imaging prodromal stages of Lewy body disease <i>Chairs: Ian Law & Javier Arbizu</i>
10:30 AM	Clinical PET DAT scanning. - <i>Ian Law (Copenhagen, Denmark)</i>
11:00 AM	Imaging Biomarkers of conversion in idiopathic rapid-eye-movement sleep behaviour disorders. - <i>Dario Arnaldi (Genoa, Italy)</i>
11:30 AM	Multi-Modal Imaging Studies of Brain-first and Body-first subtypes of Parkinson disease. - <i>Per Borghammer (Aarhus, Denmark)</i>

12:00 PM Industry symposium 2 - DaT SPECT imaging use in Lewy Body Diseases: today and in the future

Chairs: *Silvia Morbelli*

Matteo Pardini (University of Genoa)



GE HealthCare

12.45 PM Lunch

2:00 PM Lecture session 3 : Brain tumors & neuroinflammation

Chairs: *Diego Cecchin & Nathalie Albert*

2:00 PM Investigational PET tracers in neuro-oncology: present and future. - *Antoine Verger (Nancy, France)*

2:30 PM TSPO imaging in brain tumors. - *Nathalie Albert (Munich, Germany)*

3:00 PM TSPO imaging in neurodegenerative diseases. - *Donatienne Van Weehaeghe (Gent, Belgium)*

3:30 PM Coffee Break

4:00 PM Oral communications session 3

Chairs: *Antoine Verger & Silvia Morbelli*

4:00 PM Neurobiological dysfunctional substrates for the self-medication hypothesis in adult individuals with ADHD and cocaine use disorder.
Anna Lisa Martini (Italy)

4:08 PM Brain metabolic alterations in seropositive autoimmune encephalitis: an 18F-FDG PET study.
Sebastien Bergeret (France)

4:16 PM Hyperperfusion precedes demyelination in Multiple Sclerosis lesion formation : a multimodal MRI and [11C]-PiB PET study.
Théodore Soulier (France)

4:24 PM Brain network dynamics associated with self-awareness disorders in post-COVID-19 condition: fMRI co-activation patterns of the brainstem pons.
Alexandre Cionca (Switzerland)


4:32 PM C-11-SCH23390 PET reveals reduced dopamine D1 receptor availability in Gilles de la Tourette syndrome (GTS).
Konstantin Messerschmidt (Germany)

4:40 PM The contribution of early dynamic acquisition to the pathophysiological value of amyloid PET white-matter imaging in patients with multiple sclerosis.
Andrea Donniaquio (Italy)

4:48 PM Impact of SARS-CoV-2 infection on brain metabolism in neurologically asymptomatic patients using 18F-FDG PET/CT.
Paolo Mammucci (Italy)



Tuesday 14th March (Afternoon)

4:56 PM	Brain metabolic correlates of Cytokine Release Syndrome and Immune effector cell-associated neurotoxicity in Lymphoma patients treated with CART. <i>Tania Di Raimondo (Italy)</i>
5:04 PM	Little recovery of brain metabolic impairment in patient with persistent long COVID : a [18F]FDG PET study. <i>Tatiana Horowitz (France)</i>
5:15 PM	Industry symposium 3 - Fluoroethyl-L tyrosine (18F) <i>Chair: Nathalie Albert</i> <i>Marina Hodolic (Fluoroethyl-L tyrosine (18F): FET 18F-FET in patients with gliomas, from diagnosis to recurrence.) & Antoine Verger (Clinical routine in neuro-oncology, from DOPA to FET.)</i> 
6:00 PM	Rapid Fire session <i>Chairs: Federico Massa & Aida Niñerola-Baizán</i>
6:00 PM	Zolpidem's paradoxical restorative action: a case study of functional brain imaging. <i>Jennifer Boigontier (France)</i>
6:05 PM	Functional Connectivity changes in the Social Cognition network of Congenitally Blind individuals. <i>Shubham Kaushal (Israel)</i>
6:10 PM	18F-DOPA PET imaging as a marker of intratumoral heterogeneity for re-irradiation with proton therapy of recurrent glioblastoma. <i>Davide Donner (Italy)</i>
6:15 PM	Brain perfusion abnormalities in Prader-Willi infants: an arterial spin labelling - MRI study . <i>Ana Saitovitch (France)</i>
6:20 PM	A deep learning algorithm for direct attenuation correction of brain 18F-FDG PET images. <i>Ilaria Cupparo (Italy)</i>
6:30 PM	End of the day

Program

Wednesday 15th March (Morning)

8:30 AM Oral communications session 4

Chairs: Andres Perisinotti & Beatrice Orso

- | | |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 8:30 AM | Prognostic value of a normal brain FDG PET: a real-life study and associations with data from medical records and the national Alzheimer bank. - Sébastien Heyer (France) |
| 8:38 AM | A comparison of visual assessment and semi-quantification for 18F-Flortaucipir PET in a Memory Clinic cohort.- Gregory Mathoux (Switzerland) |
| 8:46 AM | The use of a biological brain age marker for monitoring treatment response in mild impaired individuals. - Caroline Dartora (Sweden) |
| 8:54 AM | Associations between a biological marker of cognitive reserve, brain pathology, and cognitive functioning. - Caroline Dartora (Sweden) |
| 9:02 AM | The metabolic correlates of apathy and unawareness of apathy differ in patients with amnesic mild cognitive impairment due to alzheimer's disease. - Federico Massa (Italy) |
| 9:10 AM | Validation of [18f]florbetaben PET quantitation based on the analysis of 15 software methods. - Audrey Perrotin (France) |
| 9:18 AM | Early-phase [18F]FBB PET vs [18F]FDG PET in atypical dementia: preliminary data from AMY-ITA study. - Luka Turk (Italy) |
| 9:26 AM | Relationship between Behavioural and Psychological Symptoms of Dementia and amyloid burden in Alzheimer's disease patients. - Chiara Maggio (Italy) |
| 9:34 AM | Differential response to donepezil across biological subtypes in prodromal alzheimer's disease. - Giulia Lorenzon (Sweden) |
| 9:42 AM | Static and dynamic functional network connectivity patterns predicting left angular gyrus-navigated rTMS efficacy in Alzheimer's disease. - Haifeng Chen (China) |
| 9:50 AM | Prediction of short and long-term poststroke cognitive impairment using clinically accessible MRI sequences and tract-based disconnection by WMH. - Renaud Lopes (France) |

10:00 AM Coffee Break

10:30 AM Lecture session 4 : White matter imaging in neurodegenerative disease and beyond

Chairs: Luca Roccatagliata & Benedetta Bodini

- | | |
|----------|--------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10:30 AM | White matter microstructure disruption in early stage amyloid pathology: is there a role for PET imaging? - Lyduine E. Collij (Amsterdam, Netherlands) |
| 11:00 AM | MRI imaging of white matter involvement in Alzheimer's Disease. - Eric Westman (Stockholm, Sweden) |
| 11:30 AM | Amyloid and TPOSO PET imaging in multiple sclerosis. - Benedetta Bodini (Paris, France) |



Wednesday 15th March (Afternoon)

12:00 PM	Rapid Fire session <i>Chairs: Andrea Chincarini & Gayane Aghakhanyan</i>
12:00 PM	18F-FET-PET multiparametrical analysis for differentiating disease relapse and pseudoprogression in real-life High Grade Glioma patients. - <i>Alessandro Spimpolo (Italy)</i>
12:05 PM	The role of the amygdala in Ictal Central Apnea: new insights from brain MRI structural morphometry. - <i>Elisa Micalizzi (Italy)</i>
12:10 PM	Clinical Validation and Correlates of the Cingulate Island Sign Visual Rating Scale for the Diagnosis of Dementia with Lewy Bodies. - <i>Linda Ruohua Feng (Denmark)</i>
12:15 PM	MonteCarlo simulation in dopaminergic neurotransmission SPECT images: toward accurate quantification methods. - <i>Aida Niñerola-Baizán (Spain)</i>
12:20 PM	Quantification of neuroinflammation using [18F]DPA-714 in patients with long-term cognitive impairment following aneurysmal subarachnoid hemorrhage. - <i>Reinier Tack (The Netherlands)</i>
12:25 PM	Cross-Modal MRI & FDG-PET Subtyping in Alzheimer's Disease. - <i>Sophia Wheatley (Sweden)</i>
12:30 PM	Familial Alzheimer's disease associated with heterozygous NPC1 mutation. - <i>Anna Lisa Martini (Italy)</i>
12:35 PM	Reproducibility of SUV-ratio (SUVr) dependent and independent methods for semiquantification of Amyloid PET: impact of spatial standardization. - <i>Francesca D'Amico (Italy)</i>
12:40 PM	Qualitative visual assessment of the cingulate island sign in a real life: a FDG- PET/ MRI study. - <i>Giovanni Zorzi (Italy)</i>
12:45 PM	Distinct reserve capacity impac DMN in response to left angular gyrus-navigated rTMS in. - <i>Tingyu Lv (China)</i>
12:50 PM	Dual tracer PET as a choice for incidental brain lesions. - <i>Fabio Magnani (Italy)</i>
12:55 PM	Synthetic Generation of Amyloid PET Images by Non-linear Dimensionality Reduction Inversion. - <i>Lorenzo Di Meco (Italy)</i>
1:00 PM	Brain response to Traumatic brachial plexus Injury. - <i>Shubham Kaushal (India)</i>
1:05 PM	Inflammation affects dynamic functional network connectivity patterns changes via plasma NFL in cognitive impairment patients. - <i>Yao Weina (China)</i>
1:10 PM	Assessing heterogeneity in longitudinal neuroimaging data: outcomes and lessons learned. - <i>Konstantinos Poulakis (Sweden)</i>
1:15 PM	The role of 18F-fluoro-ethyl-tyrosine (18F-FET) PET/MRI in patients with glioblastoma who underwent third-line therapy. - <i>Andrea Osele (Italy)</i>
1:20 PM	Patients with MRI-suspected low grade gliomas: 18F-FET or 18F-choline PET/CT? - <i>Marina Hodolic (Austria)</i>
1:25 PM	End of the day

Notes ● ---

Dotted lines for writing notes.



● Notes

A series of horizontal dotted lines providing space for taking notes.

We would like to extend a special thanks to our 2023 industry sponsors

PLATINIUM



GOLD



BRONZE



OTHER PARTNER



PATRONAGES

